Prevalence of Immunotherapy Practices in a certain region in Libya
DOI:
https://doi.org/10.54361/LJMR.20.1.07Keywords:
Cancer, Immunotherapy, Chemotherapy, and Radiation, Tripoli Teaching Medical Hospital, Sabratha Oncology Hospital, Al-Yasmeen Center for Radiotherapy, Misurata Oncology Hospital, LibyaAbstract
Background: In recent years, immunotherapy has emerged as one of the most promising approaches in cancer treatment. This therapeutic strategy enhances the body’s natural immune system to recognize and eliminate cancer cells. Unlike traditional chemotherapy and radiation therapy, immunotherapy aims to target cancer tumors while minimizing damage to healthy tissues. Aim of the Study: The study aimed to identify and evaluate key strategies that enhance the immune system’s ability to combat cancer. These strategies include the use of immune-stimulatory factors and modifications to chemotherapy protocols that support immune function. Materials and Methods: This study included 30 cancer patients recruited from several hospitals in Libya. Fifteen cases were obtained from Tripoli Teaching Medical Hospital, nine from Sabratha Oncology Hospital, five from Al-Yasmeen Center for Radiotherapy, and one case from Misurata Oncology Hospital. Data collected included age, gender, presence of chronic diseases, cancer type, and disease stage. The study was conducted over a three-month period from October to December 2023.Results: The results showed that 46.7% of the participating patients received immunotherapy, highlighting the critical role of. The immune system is a primary defense mechanism against cancer. The immune system targets cancer cells through specialized immune cells such as T lymphocytes and natural killer cells, as well as through the secretion of immune-mediated compounds that attack tumors. Conclusion: The immune system represents a fundamental barrier against cancer development and progression. Understanding immune mechanisms and the factors influencing immune responses is essential for developing more effective cancer treatment strategies, particularly in Libya.
Downloads
References
1. Arrowsmith J. Trial watch: phase III and submission failures: 2007-2010. Nat Rev Drug Discov. 2011 Feb;10(2):87.
2. Bourke JM, O'Sullivan M, Khattak MA. Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors). Med J Aust. 2016 Nov 7;205(9):418-24.
3. Chughtai B, Venkatraman G, Gressler L, Elterman D, Bhojani N. The role of manufacturer and user facility database in evaluating BPH and prostate cancer procedures. World J Urol. 2025;44(1):24.
4. Demko S, Summers J, Keegan P, Pazdur R. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. Oncologist. 2008;13(2):167-74.
5. Ebata Y, Sakaguchi Y, Tsuda Y, Nambara S, Kudou K, Kusumoto E, et al. A case of undifferentiated pleomorphic sarcoma in esophagus after multiple cancer treatments of surgery and chemoradiotherapy. Surg Case Rep. 2022 Oct 8;8(1):205.
6. Espinoza-Sánchez NA, Götte M. Role of cell surface proteoglycans in cancer immunotherapy. Semin Cancer Biol. 2020 May;62:48-67.
7. Gupta SL, Basu S, Soni V, Jaiswal RK. Immunotherapy: an alternative promising therapeutic approach against cancers. Mol Biol Rep. 2022 Oct;49(10):9903-13.
8. Johnston BJ, Novales ET. Clinical effect of Coley's toxin. II. A seven-year study. Cancer Chemother Rep. 1962 Mar;21:43-68.
9. Kao C, Charmsaz S, Tsai HL, Aziz K, Shu DH, Munjal K, et al. Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors. Nat Commun. 2025 Apr 11;16(1):3531.
10. Kienle GS. Fever in Cancer Treatment: Coley's Therapy and Epidemiologic Observations. Glob Adv Health Med. 2012 Mar;1(1):92-100.
11. Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016 May;13(5):273-90.
12. Konieczny M, Sawicka J, Gąska I, Kaczmar E, Pasek M, Kiedik A, et al. Anxiety and Depression in Breast Cancer Patients Before and After Chemotherapy: A Pre-Post Study Without a Control Group. J Clin Med. 2025 Nov;14(22):8105.
13. Korneev KV, Atretkhany KN, Drutskaya MS, Grivennikov SI, Kuprash DV, Nedospasov SA. TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis. Cytokine. 2017 Jan;89:127-135.
14. Kucerova P, Cervinkova M. Spontaneous regression of tumour and the role of microbial infection--possibilities for cancer treatment. Anticancer Drugs. 2016 Apr;27(4):269-77.
15. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006;26:154-8.
16. Mukherjee AG, Wanjari UR, Namachivayam A, Murali R. Role of Immune Cells and Receptors in Cancer Treatment: An Immunotherapeutic Approach. Vaccines (Basel). 2022 Sep 7;10(9):1493.
17. Oberneder R, Weckermann D, Ebner B, Quadt C, Kirchinger P, Raum T, et al. A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. Eur J Cancer. 2006 Oct;42(15):2530-8.
18. Prang N, Preithner S, Brischwein K, Göster P, Wöppel A, Müller J, et al. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer. 2005 Jan 31;92(2):342-9.
19. Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022 Apr 24;29(5):3044-60.
20. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016 Feb;44:51-60.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Emhamed Boras, Abtisam Dhaw, Omro Aburas, Abdulhakim Naffati (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
